Physician profile
Patrick Allan
NPI 1609954940
$15,194.15
in general payments reported to CMS, 2019-2025
44 companies · $7,076 in 2025
The $7,076 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,540 · 2020: $875 · 2021: $1,110 · 2022: $1,120 · 2023: $766 · 2024: $1,708 · 2025: $7,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $2,925 · Travel and Lodging: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $2,924.92 |
| Travel and Lodging | $1,124.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,872.35 | 2023-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $1,723.57 | 2019-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Glaxosmithkline, LLC. | $1,661.25 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $991.07 | 2019-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.59 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genentech USA, INC. | $365.22 | 2019-2023 | Xolair |
| Grifols USA, LLC | $361.36 | 2020-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $326.72 | 2019-2025 | Dupixent |
| Insmed, INC. | $262.05 | 2019-2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $219.31 | 2020-2025 | Glassia, Hyqvia |
| Philips North America LLC | $204.61 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genzyme Corporation | $203.68 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $189.93 | 2019-2024 | |
| Amgen INC. | $151.60 | 2022-2025 | Tezspire, Tavneos |
| Actelion Pharmaceuticals US, INC. | $138.31 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Allan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.